Needham & Company Maintains a 'Buy' on Gilead Sciences (GILD); Q2 Preview; Quad Pill Update
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $138.36 +0.16%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Buy' on Gilead Sciences (NASDAQ: GILD).
Analyst, Alan Carr, said, "Gilead is scheduled to report 2Q12 financial results on 7/26/12. We estimate $2.273B (was $2.272B) and $2.198B (was $2.208B) in total revenue and product sales, respectively. Our non-GAAP EPS estimate is $0.94 (unchanged). Gilead management has guided for $8.6-8.8B in 2012 product sales."
"The Quad pill PDUFA date is 8/27/12. We expect approval followed shortly thereafter by commercial launch in the U.S. Gilead plans to end active promotion of Atripla at that point, prioritizing the Quad pill followed by Complera. Launch of an over-the-counter diagnostic product for HIV (OraQuick HIV Test) is likely to favorably impact HIV product sales for Gilead." (Glaxo's (NYSE: GSK) and Pfizer's (NYSE: PFE) combined competitor Viiv reported impressive results, but Carr believes the nucleotide components of the Gilead regimen have an overall favorable long-term profile compared to those of Viiv)
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $52.83 yesterday.
Analyst, Alan Carr, said, "Gilead is scheduled to report 2Q12 financial results on 7/26/12. We estimate $2.273B (was $2.272B) and $2.198B (was $2.208B) in total revenue and product sales, respectively. Our non-GAAP EPS estimate is $0.94 (unchanged). Gilead management has guided for $8.6-8.8B in 2012 product sales."
"The Quad pill PDUFA date is 8/27/12. We expect approval followed shortly thereafter by commercial launch in the U.S. Gilead plans to end active promotion of Atripla at that point, prioritizing the Quad pill followed by Complera. Launch of an over-the-counter diagnostic product for HIV (OraQuick HIV Test) is likely to favorably impact HIV product sales for Gilead." (Glaxo's (NYSE: GSK) and Pfizer's (NYSE: PFE) combined competitor Viiv reported impressive results, but Carr believes the nucleotide components of the Gilead regimen have an overall favorable long-term profile compared to those of Viiv)
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $52.83 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
- Coherent (COHR) PT Raised to $420 at Needham
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDARelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
